DNA Insights for All: Bridging the Gap in Latino Healthcare
"Pioneering a path to personalized medicine in underserved communities through genetic research."
Precision medicine, which tailors medical treatment to the individual characteristics of each patient, holds immense potential for improving health outcomes and reducing disease burden. Ideally, this approach relies on medically actionable genetic findings, guiding interventions to mitigate or prevent disease. However, the benefits of precision medicine often remain out of reach for many, particularly those in underserved communities.
A significant limitation in current genomic research is the lack of diversity among participants and clinical settings. Racial and ethnic minorities, as well as individuals from low-income communities, are often underrepresented, hindering the generalizability and applicability of precision medicine initiatives. To address this gap, it's crucial to include diverse populations and settings in the design and implementation of these studies.
The Arizona Return of Actionable Variants Empirical (RAVE) Study, conducted in collaboration with Mountain Park Health Center (MPHC), a Federally Qualified Health Center (FQHC), aimed to expand precision medicine to a community-based primary care practice serving a predominantly Latino population. This article describes the rationale, design, procedures, and implementation framework for the Arizona RAVE study, highlighting the challenges and opportunities encountered in bringing genomic medicine to an underserved community.
Health Data and Precision Medicine Equity
The CDC’s National Center for Health Statistics describes FastStats as a source of topic-specific statistics on the health of Hispanic or Latino people. The HHS Office of Minority Health provides demographic and health summaries, including disease incidence, prevalence, and mortality among Hispanic/Latino Americans. A 2025 study discusses biomarker testing and precision medicine in Latin America through a health-equity lens, emphasizing the need to make the benefits accessible to narrow health gaps. The NIH All of Us Research Program aims to address underrepresentation in health research by building a large, diverse health database to support precision medicine.
Promise and Practical Barriers
Precision medicine uses individual characteristics to help tailor care; one review describes genetic profile, environmental factors, and lifestyle indicators as inputs to medical decision-making. The sources identify limitations ranging from data sharing to integrating precision medicine into clinical practice. For Hispanic/Latino communities, inclusive adoption requires understanding barriers and facilitators, according to a source focused on practical insights for practitioners. These materials describe an emerging approach and its implementation challenges, rather than establishing that individualized care is already consistently available.
Engaging the Community: A Collaborative Approach
The success of the Arizona RAVE study hinged on a collaborative approach that actively engaged healthcare providers, staff, and community members. Prior to enrolling participants, researchers met with MPHC leadership and primary care providers to:
- Orient clinicians to the project and its goals.
- Establish a clear process for returning actionable and nonactionable results to participants and providers through the electronic health record (EHR).
- Develop clinical decision support tools for follow-up education and care.
Returning Actionable Genetic Results
Recent work has examined clinical outcomes after actionable genetic research results are returned from a health-system research biobank. The source snippets note that some programs return results through genetic counselors, while others involve local healthcare providers who may lack the expertise or resources needed for optimal follow-up. A 2026 randomized study, the RESPECT3 study, compares digital return of actionable genetic research results with return by a genetic counselor. Separately, research on Latino populations reports that initiatives to integrate genetic testing into primary care remain pilot efforts within a single healthcare system and need expansion to address referral disparities.
Definitions, Equity, and Knowledge Gaps
The National Human Genome Research Institute definition quoted in a review describes precision medicine as generally analogous to personalized or individualized medicine and as an approach using information about an individual. A 2025 review of precision medicine for cancer in Latin America provides a view of the field’s current state, future potential, and policy and health-system context. A 2023 article calls for participation across government, healthcare, industry, clinical, academic, patient, and community groups in translating precision medicine into precision prevention. Research focused on Hispanic health also identifies major gaps in understanding how personalized medicine may shape outcomes among heterogeneous Hispanic/Latino populations and explain differences within and across demographic groups.
Lessons Learned: Bridging the Precision Medicine Gap
The Arizona RAVE study provides valuable insights into the challenges and opportunities of implementing precision medicine in underserved communities. Key lessons learned include:
Representation in Research and Care
A 2017 workshop report on personalized medicine and Hispanic health notes that many innovative treatments were developed using highly selected patient populations that may not represent clinically relevant populations. The report also describes Hispanics as underserved in healthcare, particularly in precision-medicine research and practice, and cautions that non-inclusion in research can exacerbate health disparities. In a 2026 opinion article, José Luis Cárdenas Tomažič, Dr. César Benites Chacaltana, and Sebastián Millar argue that Latin America is already practicing precision medicine, whether or not it has formally decided to do so. Together, these sources highlight representation and policy as central issues in applying precision medicine equitably.
Latino Primary Care and Market Growth
The Primary Care Latino Equity Research (PRIMER) Center convened its second annual Latino Primary Care Summit in April 2024 around the theme “Chronic Conditions in Latinos: Trends, Innovations and Care for the Future.” The summit brought together people with expertise spanning healthcare delivery, academia, policy, advocacy, and communications. A market outlook published in 2026 projects that Latin America’s precision medicine market will reach US$8,691.3 million by 2033, with an expected compound annual growth rate of 11.8% from 2026 to 2033. That figure is a market projection, while the summit source describes a convening focused on future care.
Genetic Testing in Clinical Management
A real-world data study reports that precision medicine, specifically genetic-based testing, is used in more than 140,000 individual tests to inform clinical management of disease. The source also points to databases such as the NIH Genetic Testing Registry as part of the landscape for examining this use. A separate review describes case studies and success stories in which precision medicine tailors treatment based on genetic, environmental, and lifestyle factors. The provided summaries do not specify particular diseases, patient outcomes, or individual case details.
<ul><li>Recruitment Process: Engaging and enrolling participants from underserved communities requires a resource-intensive and protracted effort, necessitating multiple contact attempts and personalized interactions.</li><li>Communication and Education: Clear, culturally sensitive communication is crucial for addressing fears and misconceptions about genetic testing and ensuring informed consent.</li><li>Community Partnerships: Collaboration with community advisory boards and healthcare providers is essential for tailoring research protocols and ensuring that interventions are culturally appropriate and aligned with community needs.</li></ul>
By addressing these challenges and fostering collaborative partnerships, it is possible to bridge the precision medicine gap and ensure that all individuals, regardless of their background or socioeconomic status, have access to the benefits of personalized healthcare.